Gilead Sciences, Inc. $GILD Shares Sold by M&G PLC

M&G PLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 22.6% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 104,368 shares of the biopharmaceutical company’s stock after selling 30,490 shares during the period. M&G PLC’s holdings in Gilead Sciences were worth $11,585,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. KBC Group NV raised its position in shares of Gilead Sciences by 26.9% during the 2nd quarter. KBC Group NV now owns 2,341,793 shares of the biopharmaceutical company’s stock worth $259,635,000 after purchasing an additional 496,708 shares during the last quarter. Advyzon Investment Management LLC raised its holdings in shares of Gilead Sciences by 6.9% during the second quarter. Advyzon Investment Management LLC now owns 2,083 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 135 shares during the last quarter. VeraBank N.A. purchased a new position in shares of Gilead Sciences in the second quarter valued at approximately $397,000. Simplify Asset Management Inc. boosted its stake in shares of Gilead Sciences by 148.6% in the second quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock worth $5,864,000 after acquiring an additional 31,618 shares during the last quarter. Finally, STF Management LP increased its position in shares of Gilead Sciences by 2.6% during the second quarter. STF Management LP now owns 19,365 shares of the biopharmaceutical company’s stock worth $2,147,000 after purchasing an additional 498 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 71,500 shares of company stock worth $8,336,040 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. TD Cowen upped their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research note on Friday, October 31st. Royal Bank Of Canada upped their price target on Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research report on Friday, October 31st. Finally, Rothschild & Co Redburn lifted their price objective on Gilead Sciences from $143.00 to $153.00 in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $128.78.

Gilead Sciences Trading Up 0.7%

NASDAQ GILD opened at $123.40 on Thursday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock has a market capitalization of $153.10 billion, a P/E ratio of 24.58, a PEG ratio of 0.81 and a beta of 0.32. The firm’s 50-day moving average is $116.99 and its two-hundred day moving average is $112.55. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $124.87.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period last year, the business earned $2.02 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio is 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.